Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Anti-Inflammatory Therapeutics Market Growth Performance Trended Historically, And What Lies Ahead?
The market size of anti-inflammatory therapeutics has shown consistent growth in the past few years. It is projected to elevate from $114.71 billion in 2024 to $117.28 billion in 2025, witnessing a compound annual growth rate (CAGR) of 2.2%. Factors contributing to growth during the historical period include the widespread occurrence of chronic diseases, an aging population, heightened awareness, and government intervention.
The market size for anti-inflammatory therapeutics is predicted to grow at a steady pace in the upcoming years, reaching a value of $142.15 billion by 2029 with a compound annual growth rate (CAGR) of 4.9%. This anticipated growth during the forecast period is as a result of innovative treatment methods, heightened healthcare spending, emphasis on curing rare illnesses, biologics and biosimilars. Key advancements expected to make a significant impact in this period include progress in immunotherapy, the incorporation of artificial intelligence (AI) and machine learning (ML) in drug discovery, and the broadening of indications.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12861&type=smp
What Are the Primary Drivers Supporting the Market Growth of the Anti-Inflammatory Therapeutics Market?
The escalating incidence of inflammatory bowel disease (IBD) is anticipated to fuel the expansion of the market for anti-inflammatory therapeutics. IBD, a persistent disease, triggers inflammation in the digestive tract. Anti-inflammatory therapeutics are pivotal in treating Crohn’s disease by lessening inflammation, managing the disease’s symptoms, and lowering the risk of surgical intervention. For example, the Oxford University Press (OUP), the university press of the University of Oxford, reported in July 2023 the IBD incidence rate at 10.9 per 100,000 person-years, and a prevalence rate of 721 per 100,000 individuals. Hence, this rising prevalence of IBD is propelling the expansion of the anti-inflammatory therapeutics market.
Which Primary Segments of the Anti-Inflammatory Therapeutics Market Are Driving Growth and Industry Transformations?
The anti-inflammatory therapeutics market covered in this report is segmented –
1) By Drug Class: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Anti-Inflammatory Biologics
2) By Indication: Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases, Other Inflammatory Diseases
3) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Distribution
Subsegments:
1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Aspirin, Naproxen, Diclofenac, Celecoxib, Indomethacin, Ketoprofen
2) By Corticosteroids: Prednisone, Dexamethasone, Hydrocortisone, Methylprednisolone, Triamcinolone, Betamethasone
3) By Anti-Inflammatory Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors, Janus Kinase (JAK) Inhibitors, Monoclonal Antibodies, Recombinant Proteins, Fusion Proteins
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=12861&type=smp
Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the Anti-Inflammatory Therapeutics Market?# Market?
North America was the largest region in the anti-inflammatory therapeutics market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-inflammatory therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Are the Most Significant Market Trends in the Anti-Inflammatory Therapeutics Market?
Leading firms in the anti-inflammatory therapeutics market are innovating and launching new drugs to reinforce their market presence. As an example, in February 2023, Regeneron Pharmaceuticals Inc. from the U.S., a firm specializing in biotechnology, along with France-based pharmaceutical and healthcare company Sanofi, introduced a new drug named Kevzara (sarilumab). This drug is unique as it’s the only anti-inflammatory biologic recommended for adult patients suffering from polymyalgia rheumatic (PMR), a type of inflammatory rheumatic disorder. It is specifically suggested for those patients who do not show adequate response to corticosteroids or those who cannot tolerate corticosteroid tapering.
View the full report here:
What Parameters Are Used to Define the Anti-Inflammatory Therapeutics Market?
Anti-inflammatory therapeutics refer to prescription medications that treat pain, lessen inflammation, and lower a high body temperature. It acts as a host response modifier and plays a crucial role in managing acute and chronic headaches, painful phases, sprains, and strain problems.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12861
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
